Megan Kruse is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 60 publications with 730 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 441952536
Telephone
216-636-2598Registry record last updated 21 Jul 2022.
Clinical trials
- Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)
Sponsor: Megan Kruse, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202511 payments$22,619openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year202515 payments$20,878openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.9%Aromatase Inhibitor47.9%Anastrozole57%Letrozole28%Exemestane15%Part D<11 patientsKinase inhibitor15.7%Kisqali51%Ibrance49%Part D<11 patients+ 1 more class in this area
Nervous system
16.1%Gabapentinoids6.2%Gabapentin100%Part D≥11 patientsOpioid Agonist5.9%Oxycodone Hcl100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
7.2%Serotonin-3 Receptor Antagonist5.1%Ondansetron Hcl100%Part D<11 patientsGLP-1 receptor agonist2.1%Mounjaro100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ASO Visual Abstract: Trends in the Management of Small HER2 Positive Breast Cancers
Annals of Surgical Oncology
2025 - Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates
International Journal of Radiation Oncology*Biology*Physics
2025 - Impact of fine particulate matter exposure on breast cancer mortality: A county-level analysis in the United States.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”